Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 940 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Localized Cancer Clear all
Completed Phase 2 Interventional

Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer

NCT00167648
View directory record Official record
Conditions
Cancer, Prostate Neoplasms
Interventions
Leuprolide or goserelin, Transdermal estradiol
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 19, 2009 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated Not applicable Interventional Results available

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

NCT02138578
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
SBRT, RFA
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 25, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional

Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Study

NCT06952790
View directory record Official record
Conditions
Cancer
Interventions
EveryDose Mobile Application
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

NCT04052555
View directory record Official record
Conditions
Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Berzosertib, Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

NCT01239355
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

NCT02076906
View directory record Official record
Conditions
Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Desmoid Tumor
Interventions
Magnetic Resonance High Intensity Focused Ultrasound
Device
Lead sponsor
AeRang Kim
Other
Eligibility
Up to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 25, 2026, 4:14 AM EDT
Recruiting Early Phase 1 Interventional

Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

NCT05291507
View directory record Official record
Conditions
Breast Cancer
Interventions
Muse MRgFUS System
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Alcohol, Breast Cancer, and Metabolism

NCT07779967
View directory record Official record
Conditions
Alcohol Drinking, Ethanol Intoxication, Breastfeeding
Interventions
Low-alcohol level exposure, Breast-pumping time
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Not listed Phase 2 Interventional

Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer

NCT00024271
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
recombinant interferon gamma, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, mitomycin C, conventional surgery, hyperthermia treatment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 25, 2026, 4:14 AM EDT
Not listed Phase 2 Interventional

Chemotherapy in Treating Patients With Liver Cancer

NCT00003044
View directory record Official record
Conditions
Liver Cancer
Interventions
cisplatin-e therapeutic implant
Drug
Lead sponsor
Matrix Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
2
States / cities
Baltimore, Maryland • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 25, 2026, 4:14 AM EDT
Recruiting Phase 2 Interventional

An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.

NCT07185165
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Computed Tomography, Fluorine F 18 Flotufolastat, Positron Emission Tomography, Ultrasound-Guided Prostate Biopsy
Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Not applicable Interventional Results available

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

NCT01985828
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT)
Radiation · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 25, 2026, 4:14 AM EDT
Active, not recruiting Phase 3 Interventional

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

NCT02446444
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Enzalutamide, Conventional NSAA, LHRHA, External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Prostate Cancer Intervention Versus Observation Trial (PIVOT)

NCT00007644
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radical prostatectomy
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Up to 75 Years · Male only
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 25, 2026, 4:14 AM EDT
Active, not recruiting Phase 2 Interventional

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

NCT04545710
View directory record Official record
Conditions
Lung Cancer
Interventions
Abemaciclib, Osimertinib
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 25, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

NCT00085410
View directory record Official record
Conditions
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 4:14 AM EDT
No Longer Available No phase listed Expanded access

Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT00589030
View directory record Official record
Conditions
Liver Cancer
Interventions
brachytherapy, yttrium Y 90 glass microspheres
Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 25, 2026, 4:14 AM EDT
Recruiting Phase 2 Interventional

Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery

NCT07686250
View directory record Official record
Conditions
Breast Cancer
Interventions
SAVI Scout MD system
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

NCT00003342
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, carboplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 25, 2026, 4:14 AM EDT
Withdrawn Not applicable Interventional

Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer

NCT02290366
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal prostate brachytherapy with Cesium-131
Radiation
Lead sponsor
Ronald M. Benoit, MD
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 25, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

MRI-Guided Ultrasound Energy in Treating Patients With Stage I, Stage II, or Stage IIIA Breast Cancer

NCT00008437
View directory record Official record
Conditions
Breast Cancer
Interventions
high-intensity focused ultrasound ablation
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Oct 25, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer and Their Family Caregivers

NCT07225855
View directory record Official record
Conditions
Localized Head and Neck Carcinoma
Interventions
Best Practice, Electronic Health Record Review, Health Communication, Interview, Office Visit, Practical Geriatric Assessment, Questionnaire Administration, Referral, Supportive Care
Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 4:14 AM EDT
Withdrawn Not applicable Interventional

Phase I Study MR-guided SBRT to PCa

NCT03935308
View directory record Official record
Conditions
Low or Intermediate Risk Prostate Cancer
Interventions
MR guided Linear Accelerator
Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 25, 2026, 4:14 AM EDT